Abstract 2852
Background
Although definitive concurrent chemoradiotherapy (CRT) is considered standard of care for most of stage III NSCLC patients, neoadjuvant treatment followed by surgery can be considered for some potentially resectable patients. Rationales for neoadjuvant treatment are tumor regression effect before surgery, early eradication of micrometastasis and better tolerability of chemotherapy than in the post-surgical setting. Regarding potential benefits of combining PD-1 blockade with CRT, here we have an ongoing phase Ib trial which assesses the safety and feasibility of the combination of neoadjuvant CRT with durvalumab in potentially resectable stage III NSCLC (NCT03694236).
Trial design
Eligible patients with histologically confirmed NSCLC (potentially resectable clinical stage III according to the American Joint Committee on Cancer 8th staging system) are enrolled. Patients receive CRT (weekly paclitaxel 45 mg/m2 and carboplatin AUC 2 with radiotherapy of 45 Gy in 25 fractions) and durvalumab (Day 1 and 29, 1500mg) during 5 weeks followed by surgery. After surgery, patients are treated with durvalumab for one year (every 4weeks, 1500 mg). The primary endpoints are safety and tolerability. The secondary endpoints are objective response rate (ORR), R0 resection rate, disease-free survival (DFS), overall survival (OS), clinical or pathological downstaging rate and, pathologic complete response (pCR) rate in the primary tumor. Immune marker analysis by FACS, exome sequencing and RNA sequencing using cancer tissue of pre-treatment, after surgery, and after recurrence will be performed.Table:
1477TiP
| Steps of trial | No. of patients | Considerations | |
|---|---|---|---|
| Neoadjuvant (weekly paclitaxel 45 mg/m2 and carboplatin AUC 2, radiotherapy 45 Gy in 25 fractions, durvalumab day 1 and 29, 1500mg) | Stage 11 | 9 | 1) If patients of ≥ 5 has grade≥3 TRAE the trial holds 2) If patients of ≤ 4 has grade≥3 TRAE the trial proceeds to the 2nd stage. |
| Stage 2 | 21 | If patients of ≤ 13(43%) has grade≥3 TRAE during the neoadjuvant treatment it will be considered tolerable and further analysis will be performed.2 | |
| Surgery | The time and modality of surgery will depend on the surgeon’s discretion. The maximum allowed interval between the end of neoadjuvant therapy and surgery is 9 weeks. If disease progresses during or after the neoadjuvant therapy, or if the surgeon thinks that the surgery is not feasible, concurrent chemoradiation or chemotherapy alone can be continued. | ||
| Adjuvant (durvalumab 1500mg for one year every 4 weeks, total of 13 times.) | The maximum allowed interval between the surgery and adjuvant therapy is 12 weeks. | ||
| Follow up | Response evaluation will be done until 5 years after the surgery.3 (Chest CT every 3 months, Abdominal pelvic CT at 1, 2, 5 years after the surgery) |
Additional enrollment will be hold until the first 9 patients proceeds surgery.
2Grade≥3 TRAE during neoadjuvant chemoradiotherapy is expected to be 30∼50% according to the previous data.
3Assessed according to the Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1. TRAE; treatment-related adverse event, CT; Computed tomography.
Clinical trial identification
NCT03694236.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract